Halozyme Therapeutics announced that Darren Snellgrove will become its Chief Financial Officer, effective June 8, 2026. Snellgrove joins the company after serving as Vice President, Investor Relations at Johnson & Johnson since May 2025 and as Chief Financial Officer of J&J’s Pharmaceuticals division from August 2021 to May 2025. Prior to that, he held senior finance roles at J&J, including CFO of the Pharmaceutical R&D division (2017‑2021) and CFO of J&J Innovation (2013‑2017).
Halozyme’s 2025 financial performance set a strong foundation for the new CFO’s mandate. Total revenue reached $1.4 billion, with royalty revenue of $868 million, and the company reiterated its 2026 guidance of $1.710 billion to $1.810 billion in revenue, $1.130 billion to $1.170 billion in royalty revenue, and adjusted EBITDA of $1.125 billion to $1.205 billion. Non‑GAAP diluted EPS is projected to grow 87% to 99% year‑over‑year, to $7.75–$8.25.
Strategically, Halozyme has been expanding its drug‑delivery portfolio through acquisitions such as Surf Bio and the Hypercon™ technology, extending the life of its ENHANZE platform beyond the 2027 patent expiration. The company’s royalty‑driven model, supported by high‑profile partners and durable streams, underpins its growth strategy and provides a stable cash source for capital deployment and shareholder returns.
"I am delighted to have a financial leader of Darren’s experience and caliber join Halozyme at this exciting time. He is a highly respected finance leader with deep experience and an expansive skillset, demonstrated by successful leadership across major portfolio investments and a strong, well‑established record of investor engagement," said President and CEO Helen Torley. "I look forward to having Darren join our leadership team and contribute to the acceleration of value creation for our shareholders."
"I am thrilled to join Halozyme at such an important time in the Company’s evolution. Halozyme’s technology has dramatically improved the delivery of biologics for patients, and the company has built a broad technology portfolio with strong partners, durable royalty streams, and significant long‑term opportunity. I look forward to working with Helen and the entire team to drive sustainable growth and value creation for shareholders," said Snellgrove.
With a seasoned finance executive at the helm, Halozyme aims to maintain its sub‑1x net debt/EBITDA target while funding new platform developments and expanding its royalty‑driven business model. Snellgrove’s track record in capital allocation and investor relations positions the company to continue disciplined capital deployment, support ongoing acquisitions, and sustain shareholder return programs.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.